Depemokimab (1) – Exdensur®

Bronchial asthma, ≥ 12 years

Characteristics

Start date 01.04.2026
Resolution 01.10.2026 – active procedure
INN Depemokimab
Brand name Exdensur®
Pharm. company GlaxoSmithKline GmbH & Co. KG
G-BA Procedure ID D-1310
Therapeutic area Respiratory system diseases
Reason for procedure Initial assessment

Associated procedures

Depemokimab (2) Exdensur® GlaxoSmithKline GmbH & Co. KG Respiratory system diseases Chronic rhinosinusitis with nasal polyps n.d. active procedure
Depemokimab (1) Exdensur® GlaxoSmithKline GmbH & Co. KG Respiratory system diseases Bronchial asthma, ≥ 12 years n.d. active procedure


<< List of all resolutions